NCT00608803已完成1 期
A Phase I Study of ZIO-201-T in Combination With Doxorubicin in Subjects With Advanced, Refractory Solid Tumors for Which no Standard Therapy Exists and for Whom Treatment With Doxorubicin is Considered Medically Acceptable
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 主要终点
- Toxicities
研究概览
简要总结
The study of safety of ZIO-201-T in combination with doxorubicin in the treatment of advanced cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Histological or cytological documentation of cancer
- •Measurable disease
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •Ifosfamide and doxorubicin naïve
- •Life expectancy of at least 12 weeks
- •Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements conducted within 7 days prior to dosing:Hemoglobin >9.0 g/dL, Absolute neutrophil count (ANC) >1,500/mm3,Platelet count ≥100,000/mm3,Total bilirubin <1.5×ULN,ALT and AST ≤2.5×ULN,Partial thromboplastin [PT]-INR/activated partial thromboplastin time [PTT] <1.5×ULN. Subjects who are being therapeutically anticoagulated with an agent such as Coumadin (warfarin sodium) or heparin are allowed provided there is no prior evidence of underlying abnormality in coagulation parameters. If an interaction between study drug and anticoagulant is suspected, anticoagulation monitoring should be increased as appropriate. Serum creatinine ≤ULN
- •Written, informed consent must be obtained from a potential subject prior to the conduct of any study-specific procedures
- •Male and female subjects must agree to use adequate birth control measures/barrier control during the course of the trial.
- •Women of childbearing potential must have a pregnancy test performed within 7 days of the start of treatment.
排除标准
- •Clinically evident congestive heart failure >Class II of the New York Heart Association (NYHA) guidelines
- •Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia, or ventricular arrhythmias classified as Lown III, IV, or V
- •History and/or signs of active coronary artery disease/ischemia with or without angina pectoris
- •Serious myocardial dysfunction defined as scintigraphically (MUGA, myocardial scintigram) determined absolute left ventricular ejection fraction (LVEF) below 45% or an LVEF below the normal limit (one or both criteria is sufficient for exclusion)
- •History of HIV infection
- •Prior nephrectomy of history of urinary tract obstruction
- •Active, clinically serious infection requiring systemic antibacterial, antifungal, or antiviral therapy
- •Any major surgery within 3 weeks prior to start of treatment
- •Metastatic brain or meningeal tumors, unless the subject is >6 months from definitive therapy and has a negative imaging study within 4 weeks of study entry. In addition, the subject must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable, provided the dose is stable for 1 month prior to study start, and following screening radiographic studies).
- •History of seizure disorder (a subject with seizures related to brain metastasis will be allowed provided he/she has been seizure-free for at least 2 months and meets the criteria defined above for inclusion of subjects with brain metastasis)
- •Previous malignancy (except cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumors [Ta, Tis, & T1] or other malignancies curatively treated >3 years prior to entry)
- •Pregnancy or lactation
- •Substance abuse or medical, psychological, or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
- •Any condition that is unstable or could jeopardize the safety of a subject and his/her compliance with the protocol requirements
研究组 & 干预措施
Single arm
Experimental
Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
干预措施: ZIO-201-T and doxorubicin (Drug)
结局指标
主要结局
Toxicities
时间窗: 5 months
次要结局
- Pharmacokinetics(5 months)
研究者
相似试验
已完成
1 期
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaAdult AngiosarcomaAdult Desmoplastic Small Round Cell TumorAdult Epithelioid SarcomaAdult Extraskeletal Myxoid ChondrosarcomaAdult Extraskeletal OsteosarcomaAdult FibrosarcomaAdult LeiomyosarcomaAdult LiposarcomaAdult Malignant MesenchymomaAdult Malignant Peripheral Nerve Sheath TumorAdult RhabdomyosarcomaAdult Synovial SarcomaAdult Undifferentiated High Grade Pleomorphic Sarcoma of BoneChildhood AngiosarcomaChildhood Desmoplastic Small Round Cell TumorChildhood Epithelioid SarcomaChildhood FibrosarcomaChildhood LeiomyosarcomaChildhood LiposarcomaChildhood Malignant MesenchymomaChildhood Malignant Peripheral Nerve Sheath TumorChildhood Pleomorphic RhabdomyosarcomaChildhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar FeaturesChildhood Synovial SarcomaMalignant Adult HemangiopericytomaMalignant Childhood HemangiopericytomaMetastatic Childhood Soft Tissue SarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaStage III Adult Soft Tissue SarcomaStage IV Adult Soft Tissue SarcomaUntreated Childhood RhabdomyosarcomaDermatofibrosarcoma ProtuberansNCT00720174National Cancer Institute (NCI)30
已完成
1 期
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial CancerEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaStage III Uterine Corpus CancerStage IV Uterine Corpus CancerNCT00005830Gynecologic Oncology Group31
已完成
1 期
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory B Lymphoblastic LymphomaNCT03991884University of Washington24
已完成
1 期
A Phase I Trial of ZIO-101 in Solid TumorsSolid TumorsNCT00591396Alaunos Therapeutics40
已完成
1 期
A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00000954National Institute of Allergy and Infectious Diseases (NIAID)72